Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial
Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from its ongoing Phase 1b/2a RESOLVE trial. The ... Read More